ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics

Rhea-AI Summary

ZETA SURGICAL and HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), reported the first patient treated with the FDA-cleared Zeta TMS Navigation System at a Sarasota clinic on June 23, 2026.

Systems are installed in Sarasota and West Palm Beach, using AI-based RealTrack™ image guidance for sub-millimetric TMS targeting in treatment-resistant depression and other neuropsychiatric conditions.

Positive

• First patient treated using FDA-cleared Zeta TMS Navigation System at HOPE clinic
• Zeta TMS systems installed at two HOPE Therapeutics clinics in Florida
• RealTrack technology offers sub-millimetric, markerless TMS coil positioning accuracy
• AI-driven registration of MRI or CT to facial anatomy in under two minutes
• System incorporated into outpatient workflows for major depressive disorder patients

Negative

• None.

News Market Reaction – NRXP

-3.59%

32 alerts

-3.59% Session close to close

-10.4% Trough in 25 min

$125.35M Market Cap

0.9x Rel. Volume

In the Jun 23 session, NRXP declined 3.59%, reflecting a moderate negative market reaction. Argus tracked a trough of -10.4% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement extends NRXP’s TMS-focused strategy, as HOPE clinics start treating patients with ...

Analysis

This announcement extends NRXP’s TMS-focused strategy, as HOPE clinics start treating patients with Zeta’s navigation system to enhance precision. With an effective $150,000,000 shelf and high short interest, funding choices and sentiment shifts remain key to monitor.

Key Figures

Prevalence in MDD: one-third of patients Registration time: under two minutes Targeting accuracy: sub-millimetric accuracy

3 metrics

Prevalence in MDD one-third of patients Share of major depressive disorder patients affected by treatment-resistant depression

Registration time under two minutes Time to register MRI or CT to patient’s facial anatomy with Zeta TMS system

Targeting accuracy sub-millimetric accuracy Accuracy of TMS coil tracking relative to planned brain target

Historical Context

5 past events · Latest: Jun 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 22	FDA expanded access	Positive	-2.6%	FDA cleared expanded access protocol for NRX-101 to augment TMS in depression.
Jun 05	Clinical data highlight	Positive	+2.2%	Conference data showed higher IV ketamine efficacy vs nasal esketamine in depression.
Jun 04	Equity offering close	Negative	+2.2%	Closed $22.3M common stock offering at $3.50 per share including option exercise.
Jun 03	Equity offering pricing	Negative	-12.3%	Priced underwritten equity offering using S-3 shelf to raise up to $23M gross.
Jun 02	Equity offering plan	Negative	-12.3%	Announced proposed underwritten common stock offering under effective S-3 shelf.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent NRXP news often triggers sizable moves, with mixed alignment between headline tone and next-day price reaction.

Key Terms

tms, treatment-resistant depression, major depressive disorder, computer vision

4 terms

tms medical

"TMS is a non-invasive therapy used primarily for treatment-resistant depression"

Transcranial magnetic stimulation is a noninvasive medical treatment that uses brief magnetic pulses to stimulate specific areas of the brain, similar to tapping a circuit to reset its activity. Investors watch TMS because approvals, clinical trial results, or wider insurance coverage can open large markets for devices and services, affecting revenue and growth prospects for companies developing or delivering the therapy.

treatment-resistant depression medical

"TMS is a non-invasive therapy used primarily for treatment-resistant depression"

A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.

major depressive disorder medical

"which affects approximately one-third of patients with major depressive disorder"

A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.

computer vision technical

"applies artificial intelligence and computer vision to register a patient's MRI or CT"

Computer vision is technology that gives machines the ability to 'see' and make sense of images or video, turning pixels into usable information like object counts, measurements, or activity patterns. For investors, it matters because it enables automation, cost reduction and new product features across industries—from quality checks on factory lines to retail analytics—so companies that adopt effective computer vision can boost efficiency, reduce labor needs and create competitive advantages.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SARASOTA, Fla, and BOSTON, June 23, 2026 /PRNewswire/ -- ZETA SURGICAL and HOPE Therapeutics, an NRx Pharmaceuticals company (Nasdaq: NRXP), today announced the first patient treatment with the FDA-cleared Zeta TMS Navigation System at a HOPE Therapeutics clinic in Sarasota. HOPE has installed Zeta TMS Navigation Systems at clinics in West Palm Beach and Sarasota, with Zeta-navigated patient treatments beginning at both locations this week.

TMS is a non-invasive therapy used primarily for treatment-resistant depression, which affects approximately one-third of patients with major depressive disorder. TMS is also used in other neuropsychiatric conditions, including obsessive-compulsive disorder and other disorders involving brain circuit dysfunction. Because TMS is intended to modulate specific brain regions and neural circuits, accurate and repeatable targeting of patient-specific treatment sites is an important component of treatment delivery.

The Zeta TMS Navigation System uses proprietary RealTrack™ technology to provide real-time, markerless image guidance for TMS procedures. The system applies artificial intelligence and computer vision to register a patient's MRI or CT imaging to their facial anatomy in under two minutes and continuously track the position of the TMS coil relative to the planned brain target with sub-millimetric accuracy. At HOPE, the system has been incorporated into outpatient TMS workflows for eligible patients, including those receiving treatment for major depressive disorder.

"Beginning patient treatments with the Zeta TMS Navigation System marks a major milestone in bringing surgical-grade accuracy to the TMS clinic," said Raahil Sha, Co-Founder and Chief Technology Officer of ZETA. "We are excited to see our technology now supporting real patients in the treatment of depression, and to support clinicians in expanding access to more personalized, precision-guided TMS across the country."

Dr. Rebecca Cohen, Medical Director of HOPE Therapeutics, comments: "The continued evolution of precision TMS technology is transforming what's possible in psychiatric care. I am inspired by the increased accuracy, reliability and personalized care that these ZETA advancements provide, and honored to offer this cutting-edge treatment to patients across our HOPE Therapeutics clinics, helping improve outcomes and quality of life."

About ZETA SURGICAL

ZETA SURGICAL is redefining the standard of care for image-guided surgery and targeted neuro-therapeutics. Its navigation and robotics platform applies advanced artificial intelligence and computer vision to enable high-accuracy image guidance across virtually any point of care in minutes, unlocking less invasive and more precise targeted therapies. The Zeta Navigation System and Zeta TMS Navigation System are cleared by the FDA and commercially available in the United States.

For more information, please visit www.zetasurgical.com.

Media Contact — media@zetasurgical.com

About HOPE Therapeutics

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), is a provider of advanced psychiatric and neurological care, specializing in evidence-based treatments for major depressive disorder, anxiety, and other complex neurological conditions. Operating out of state-of-the-art clinics, HOPE Therapeutics focuses on improving patient outcomes through the application of modern medical technologies and clinical practices.

For more information, please visit www.hopetherapeutics.com.

Media Contact — brian.korb@astrpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/zeta-surgical-announces-successful-treatment-of-first-patient-with-zeta-tms-navigation-system-at-hope-therapeutics-302807926.html

SOURCE Zeta Surgical

FAQ

What did NRx Pharmaceuticals (NRXP) announce about the Zeta TMS Navigation System on June 23, 2026?

NRx Pharmaceuticals, via HOPE Therapeutics, announced first patient treatment using the FDA-cleared Zeta TMS Navigation System. According to ZETA SURGICAL, the system is operating in Sarasota and West Palm Beach clinics, guiding TMS with AI-based, real-time image navigation.

What is the Zeta TMS Navigation System used by HOPE Therapeutics and how does it work?

The Zeta TMS Navigation System guides transcranial magnetic stimulation treatments for depression and other neuropsychiatric conditions. According to ZETA SURGICAL, it uses AI and computer vision to align MRI or CT scans to facial anatomy and track coil position with sub-millimetric accuracy.

Which HOPE Therapeutics clinics of NRx Pharmaceuticals (NRXP) are using the Zeta TMS Navigation System?

HOPE Therapeutics has installed Zeta TMS Navigation Systems in its Sarasota and West Palm Beach clinics. According to HOPE Therapeutics, Zeta-navigated patient treatments are beginning at both Florida locations, integrating navigation into outpatient TMS workflows for eligible patients.

How does the Zeta TMS Navigation System aim to improve treatment-resistant depression outcomes?

The system aims to improve care by enabling accurate, repeatable targeting of brain regions during TMS. According to ZETA SURGICAL, its RealTrack technology continuously tracks coil position relative to planned brain targets, supporting more personalized and precision-guided treatments for major depressive disorder.

Is the Zeta TMS Navigation System already FDA-cleared and commercially available for NRXP-related clinics?

Yes, the Zeta TMS Navigation System is FDA-cleared and commercially available in the United States. According to ZETA SURGICAL, HOPE Therapeutics clinics operated by NRx Pharmaceuticals are among the first to use the system in routine psychiatric and neurological care.

What medical conditions are HOPE Therapeutics and ZETA SURGICAL targeting with the Zeta TMS Navigation System?

They are targeting major depressive disorder, treatment-resistant depression, obsessive-compulsive disorder, and other brain circuit disorders. According to HOPE Therapeutics, the clinics specialize in evidence-based psychiatric and neurological care using modern technologies like precision-guided TMS.